Primary brain tumors (PBTs) are uncommon among the general population. Molecularly distinct PBTs in the same individual are even rarer and generally occur in the context of specific well-characterized hereditary cancer syndromes or in exposure to high-risk environmental factors such as remote CNS irradiation. In...
Aditya Pisupati, J. Wefel, S. Bajaj et al.· Neuro-Oncology· 0 citations
Unmethylated MGMT promoter status occurs in 60% of glioblastoma (GBM) cases, driving active DNA-repair enzyme production, severe temozolomide resistance, and a dismal median overall survival under 16 months. Despite this poor prognosis, a rare subset of unmethylated GBM (uMGMT-GBM) patients achieve unexpected lon...
Marine Isakadze, Serena Cutarella, J. Wefel et al.· Neuro-Oncology· 0 citations
NF1-associated high-grade gliomas (HGGs) are rare, biologically heterogeneous tumors with poor outcomes. Although MEK inhibitors (MEKis) are established options for selected NF1-associated low-grade gliomas, their role in NF1-associated HGG remains undefined. We describe clinical and radiographic outcomes with MEKis, i...
Ming-Chun Yu, Aileen H. Hsi, Aqsa Adnan et al.· Journal of Neuro-Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.